慢性肝病致骨质疏松症的机制及防治

段志军; 郑淼磊; 李钰伶; 崔东升

慢性肝病致骨质疏松症的机制及防治

大连医科大学附属第一医院消化科

基金项目:

国家自然科学基金资助项目(30970886)；

详细信息

中图分类号: R580
计量
- 文章访问数: 384
- HTML全文浏览量: 27
- PDF下载量: 189
- 被引次数: 0
出版历程
- 出版日期: 2012-08-20

Mechanism, prevention and treatment of osteoporosis in chronic liver disease

Research funding:

摘要

摘要: 我国慢性肝病(CLD)极为常见,其中一部分并发症和(或)伴发病严重,预后差。近年CLD与钙磷代谢及骨疾病关系的研究已成为国内外关注的热点。CLD可致肝性骨营养不良,而骨质疏松症(OP)又是最常见的肝性骨营养不良类型。因CLD原发病症状体征的存在,及OP缺乏典型临床表现,OP常被忽视。当伴发自发性骨折或低创伤性骨折时,严重影响了患者的生活质量,甚至危及生命。本文就各种CLD和OP的关系,CLD致OP的机制,以及CLD合并OP的防治对策加以综述,对及时有效地纠正CLD发展过程中OP的发生具有重要临床意义。
- 慢性肝病 /
- 骨质疏松
Abstract: Chronic liver disease (CLD) is very common in China.Moreover, CLD is associated with poor prognosis due to subsequent development of severe complications and diseases that lower the quality of life and increase the risk of death.Osteoporosis (OP) is one of the most frequently diagnosed CLD-related hepatic osteodystrophies;and when combined with spontaneous fracture or low trauma fracture, OP can be particularly life-threatening.Unfortunately, CLD-related OP is often overlooked, due to the presence of CLD primary disease signs and symptoms, and lack of typical OP clinical manifestations.In recent years, extensive global research efforts have been dedicated to uncovering the relationship between calcium and phosphorus metabolism and CLD-related bone disease.This review focuses on the current knowledge about the relationship between CLD and OP, systematically discussing the underlying mechanism and strategies to prevent and treat CLD-related OP.Increasing our comprehensive understanding of this molecular and clinical features of this pathogenic process will facilitate effective and timely diagnosis and therapeutic intervention.
- chronic liver disease /
- osteoporosis

HTML全文

参考文献(49)

[1]Leboime A, Confavreux CB, Mehsen N, et al.Osteoporosis andmortality[J].Joint Bone Spine, 2010, 77 (Suppl 2) :S107-112.

[2]Kanis JA.Assessment of fracture risk and its application toscreening for postmenopausal osteoporosis:synopsis of aWHO report.WHO Study Group[J].Osteoporosis Int, 1994, 4 (6) :368-381.

[3]Wariaghli G, Mounach A, Achemlal L, et al.Osteoporosis inchronic liver disease:a case-control study[J].RheumatolInt, 2010, 30 (7) :893-899.

[4]Dorothy J, Vander J, Edith O, et al.Use of calcaneal ultra-sound and biochemical markers to assess the density andmetabolic state of the bones of adults with hepatic cirrhosis[J].J Natl Med Assoc, 2007, 99 (9) :1024-1029.

[5]Taveira A, Pereira F, Fernandes M, et al.Longitudinal evalu-ation of hepatic osteodystrophy in children and adolescentswith chronic cholestatic liver disease[J].Braz J Med BioRes, 2010, 43 (11) :1127-1134.

[6]Jeffrey PL.Identification, diagnosis, and prevention of oste-oporosis[J].The American journal of managed care, 2011, 17:170-176.

[7]Bernstein C, Leslie W, Leboff M.AGA technical review onosteoporosis in gastrointestinal disease[J].Gastroenterolo-gy, 2003, 124 (3) :795-841.

[8]Raisz LG.Pathogenesis of osteoporosis:concepts, conflicts, andprospects[J].J Clin Invest, 2005, 115 (12) :3318-3325.

[9]Goral V, Simsek M, Mete N.Hepatic osteodystrophyand liver cir-rhosis[J].World J Gastroenterol, 2010, 16 (13) :1639-1643.

[10]Collier J.Bone disorders in chronic liver disease[J].Hepatol-ogy, 2007, 46 (4) :1271-1278.

[11]Sif O, Osten L, Hans M, et al.Increased rate of bone lossat the femoral neck in patients with chronic liver disease[J].Eur J Gastroenterol Hepatol, 2002, 14 (1) :43-48.

[12]Schiefke I, Fach A, Wiedmann M, et al.Reduced bonemi-neral density and altered bone turnover markersin patientswith non-cirrhotic chronic hepatitis B or C infection[J].World J Gastroenterol, 2005, 11 (12) :1843-1847.

[13]Cijevschi C, Mihai C, Drug VL, et al.Osteoporosis in livercirrhosis-overview[J].Rev Med Chir Soc Med Nat Iasi, 2005, 109 (4) :700-704.

[14]Mounach A, Ouzzif Z, Wariaghli G, et al.Primary biliary cir-rhosis and osteoporosis:a case-control study[J].J BoneMiner Metab, 2008, 26 (4) :379-384.

[15]George J, Ganesh HK, Acharya S, et al.Bone mineral densityand disorders of mineral metabolism in chronic liver disease[J].World J Gastroenterol, 2009, 15 (28) :3516-3522.

[16]Guanabens N, Pares A.Management of osteoporosis in liverdisease[J].Clin Res Hepatol Gastroenterol, 2011, 35 (6-7) :438-445.

[17]Pusl T, Beuers U.Extrahepatic manifestations of cholestaticliver diseases pathogenesis and therapy[J].Clin Rev AllergyImmunol, 2005, 28 (2) :147-157.

[18]Leslie WD, Bernstein CN, Leboff MS, et al.AGA technialreview on osteoporosis in hepatic disorders[J].Gastroenter-ology, 2003, 125 (3) :941-966.

[19]Wolfhag en FH, van Buur en HR, Vleggaar FP, et al.Manage-ment of osteoporosis in primary biliary cirrhosis[J].BaillieresBest Pract Res Clin Gast roenterol, 2000, 14 (4) :629-641.

[20]Guichelaar M, Malinchoc M, Sibonga J, et al.Bone metabolismin advanced cholestatic liver disease:analysis by bone histo-morphometry[J].Hepatology, 2002, 36 (4) :895-903.

[21]Moreira R, Duarte M, Farias M.Disturbances of calcium-PTH-vitamin D axis in chronic liver disease[J].Arq BrasEndocrinolMetabol, 2004, 48 (4) :443-450.

[22]邴玉芝, 姚宏昌, 张自新, 等.慢性肝病患者骨营养不良的临床分析[J].实用肝脏病杂志, 2004, 7 (1) :46-47.

[23]Luxon BA.Bone disorders in chronic liver diseases[J].CurrGastroenterol Rep, 2011, 13 (1) :40-48.

[24]Albuquerque Taveira A, Fernandes M, Galvao L, et al.Im-pairment of bone mass development in children with chroniccholestatic liver disease[J].ClinEndocrinol (oxf) , 2007, 66 (4) :518-523.

[25]Capparelli C, Morony S, Warmington K, et al.Sustained an-tiresorptive effects after a single treatment with human re-combinant osteoprotegerin (OPG) :a pharmacodynamic andpharmacokinetic analysis in rats[J].J Bone Miner Res, 2003, 18 (5) :852-858.

[26]Crawford B, Labio E, Strasser S, et al.Vitamin D replace-ment for cirrhosis-related bone disease[J].GastroenterolHepatol, 2006, 3 (12) :689-699.

[27]Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Santo-laria-Fernandez F, et al.Serum osteoprotegerin and RANKLlevels in chronic alcoholic liver disease[J].Alcohol, 2006, 41 (3) :261-266.

[28]Pignata S, Daniele B, Galati M, et al.Oestradiol and testos-terone levels in patients with viral cirrhosis and hepatocellularcarcinoma[J].Eur J Gastroenterol Hepatol, 1997, 9 (3) :283-286.

[29]陈如山, 阎德文, 王建平, 等.慢性乙肝性肝硬化症男性患者血清性激素、钙调节激素和骨转换指标的变化[J].中国骨质疏松杂志, 2002, 8 (3) :230-233.

[30]Loria I, Albanese C, Giusto M, et al.Bone disorders in pa-tients with chronic liver isease awaiting liver transplantation[J].Transplant Proc, 2010, 42 (4) :1191-1193.

[31]Crawford BA, Labio ED, Strasser SI, et al.Vitamin D re-placement for cirrhosis-related bone disease[J].Nat ClinPract Gastroenterol Hepatol, 2006, 3 (12) :689-699.

[32]Leslie W, Bernstein C, Leboff M, et al.AGA technical re-view on osteoporosis in hepatic disorders[J].Gastroenterol-ogy, 2003, 125 (3) :941-966.

[33]Boone RH, Cheung AM, Girlan LM, et al.Osteoporosis inprimary biliary cirrhosis:a randomized trial of the efficacy andfeasibility of estrogen/progestin[J].Dig Dis Sci, 2006, 51 (6) :1103-1112.

[34]Ormarsdottis S, Mallmin H, Naessen T, et al.An open, ran-domized, controlled study of transdermal hormone replace-ment therapy on the rate of bone loss in primary billiary cir-rhosis[J].J Intern Med, 2004, 256 (1) :63-69.

[35]Pereira S, Donohue J, Moniz C, et al.Trandermal hormonalreplacement therapy improves vertebral bone density in pri-mary biliary cirrhosis:results of a 1-year controlled trial[J].Aliment Pharmacol Ther, 2004, 19 (5) :563-570.

[36]Hay J, Guichelaar M.Evaluation and management of osteopo-rosis in liver disease[J].Clin Liver Dis, 2005, 9 (4) :747-766.

[37]张小玉, 王雷, 陆重琳, 等.雷洛昔芬治疗慢性肝病并发骨质疏松症患者40例分析[J].实用医学杂志, 2005, 21 (3) :306-307.

[38]David M Reid, Jean-Pierre Devogelaer, Kenneth Saag, et al.Zoledronic acid and risedronate in the prevention and treatmentof glucocorticoid-induced osteoporosis (HORIZON) :a multi-centre, double-blind, double-dummy, randomised controlledtrial[J].Lancet, 2009, 373 (6971) :1253-1263.

[39]Crawford B, Kam C, Pavlovic J, et al.Zoledronic acid pre-vents bone loss after liver transplantation:a randomized, double-blind, placebo-controlled trial[J].Ann InternMed, 2006, 144 (4) :239-248.

[40]Millonig G, Graziadei I, Eichler D, et al.Alendronate in com-bination with calcium and vitamin D prevents bone loss afterorthotropic liver transplantation:a prospective single-centerstudy[J].Liver Tanspl, 2005, 11 (8) :960-966.

[41]Zein C, Jorgensen R, Clarke B, et al.Alendronate improvesbone mineral density in primary biliary cirrhosis:a randomizedplacebo-controlled trial[J].Hepatology, 2005, 42 (4) :762-771.

[42]Lewiecki EM.Safety of long-term bisphosphonate therapyfor the management of osteoporosis[J].Drugs, 2011, 71 (6) :791-814.

[43]Cranney A, Tugwell P, Zytaruk N, et al.Meta-analysis oftherapies for postmenopausal osteoporosis.VI.Meta-anal-ysis of calcitonin for the treatment of postmenopausal osteo-porosis[J].Endocr Rev, 2002, 23 (4) :540-551.

[44]Camisasca M, Crosignani A, Battezzati P, et al.Parenteralcalcitonin for metabolic bone disease associated with primarybiliary cirrhosis[J].Hepatology, 1994, 20 (3) :633-637.

[45]Zhang M, Huang F, Tan Y, et al.Effect of sodium fluorideon bone turnover and bone loss of vertebrae and tibia inovariectomized rats[J].Zhonghua Bing Li Xue Za Zhi, 2000, 29 (1) :49-52.

[46]张超, 朱勇.经皮椎体成形及后突成形在脊柱外科的应用现状[J].实用骨科杂志, 2003, 9 (6) :505-508.

[47]林伯庚, 陈治卿, 陈鹭玲.降钙素对骨质疏松症治疗的临床观察[J].中国骨质疏松杂志, 2006, 12 (5) :490-491.

[48]Arase Y, Suzuki F, Suzuki Y, et al.Virus clearance reducesbone fracture in postmenopausal women with osteoporosisand chronic liver disease caused by hepatitis C virus[J].JMed Virol, 2010, 82 (3) :390-395.

[49]Guichelaar M, Kendall R, Malinchoc M, et al.Bone mineraldensity before and after OLT:long-term follow-up and pre-dictive factors[J].Liver Transpl, 2006, 12 (9) :1390-1402.

施引文献

资源附件(0)

访问统计